Unicycive Therapeutics (UNCY) Net Cash Flow (2020 - 2026)
Unicycive Therapeutics' (UNCY) quarterly Net Cash Flow came in at $8.2 million in Q1 2026, up 228.24% YoY from $2.5 million in Q1 2025, and up 160.55% on a QoQ basis from -$13.5 million in Q4 2025.
Unicycive Therapeutics (UNCY) Net Cash Flow (2020 - 2026) Analysis & Trends
Unicycive Therapeutics (UNCY) has 7 years of Net Cash Flow data on file, last reported at $8.2 million in Q1 2026.
- Quarterly Net Cash Flow rose 228.24% year-over-year to $8.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $17.6 million (up 160.36% YoY) and the FY2025 annual result came in at $3.1 million, down 81.41% from the prior year.
- Net Cash Flow advanced to $8.2 million in Q1 2026, from -$13.5 million in the prior quarter.
- In the past five years, Net Cash Flow ranged from a high of $39.2 million in Q1 2024 to a low of -$13.5 million in Q4 2025.
- A 5-year average of $1.3 million and a median of -$4.5 million in 2023 frame the typical range for Net Cash Flow.
- Annual changes were most pronounced in 2022 — Net Cash Flow tumbled 2112.93% — and 2023, when it soared 906.93%.
- Tracing UNCY's Net Cash Flow over 5 years: stood at -$6.1 million in 2022, then grew by 23.67% to -$4.6 million in 2023, then tumbled by 33.61% to -$6.2 million in 2024, then slumped by 117.52% to -$13.5 million in 2025, then surged by 160.55% to $8.2 million in 2026.
- The last three Net Cash Flow figures came in at $8.2 million (Q1 2026), -$13.5 million (Q4 2025), and $20.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -496,000.00 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -37.14 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 225.59 Mn |
| 10 | Unicycive Therapeutics | 151.01 Mn | 151.01 Mn | - | 6.81 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 6.81 Mn |
| Jun 30, 2026 | 6.81 Mn |
| Mar 31, 2026 | 8.17 Mn |
| Mar 31, 2026 | 8.17 Mn |
| Dec 31, 2025 | -13.50 Mn |
| Dec 31, 2025 | -13.50 Mn |
| Sep 30, 2025 | 20.37 Mn |
| Sep 30, 2025 | 20.37 Mn |
| Jun 30, 2025 | 2.56 Mn |
| Jun 30, 2025 | 2.56 Mn |
| Mar 31, 2025 | -6.37 Mn |
| Mar 31, 2025 | -6.37 Mn |
| Dec 31, 2024 | -6.21 Mn |
| Dec 31, 2024 | -6.21 Mn |
| Sep 30, 2024 | -9.43 Mn |
| Sep 30, 2024 | -9.43 Mn |
| Jun 30, 2024 | -7.15 Mn |
| Jun 30, 2024 | -7.15 Mn |
| Mar 31, 2024 | 39.23 Mn |
| Mar 31, 2024 | 39.23 Mn |